SCHEMBL2676359

SCHEMBL2676359

O=C1CCC(N2CCCc3cc(Br)ccc32)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 7/20 0.44
HTR2B P41595 7/20 0.44
PDK1 Q15118 2/20 0.41
PDK2 Q15119 2/20 0.41
PDK3 Q15120 2/20 0.41
PDK4 Q16654 2/20 0.41
SRD5A1 P18405 1/20 0.40
DPP4 P27487 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NOS1 P29475 2/20 0.36
NOS3 P29474 1/20 0.36
CYP2C19 P33261 1/20 0.36
SLC22A12 Q96S37 1/20 0.35
ABHD6 Q9BV23 1/20 0.34
HTR6 P50406 1/20 0.34
AVPR1A P37288 1/20 0.34
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676180 0.91 DPP4 (0.46) HTR2CHTR2BPDK1PDK2PDK3
SCHEMBL2676037 0.84 NOS1 (0.49) HTR2CHTR2BPDK1PDK2PDK3
SCHEMBL13381031 0.83 HTR2C (0.41) HTR2CHTR2BPDK1PDK2PDK3
SCHEMBL16948342 0.82 HTR2C (0.43) HTR2CHTR2BPDK1PDK2PDK3
SCHEMBL27778240 0.81 PDK1 (0.44) HTR2CHTR2BPDK1PDK2PDK3
SCHEMBL2675880 0.80 NOS1 (0.50) HTR2CHTR2BSRD5A1DPP4HDAC1
SCHEMBL10272035 0.80 HTR2C (0.39) HTR2CHTR2BPDK1PDK2PDK3
SCHEMBL2675577 0.80 NOS1 (0.45) HTR2CHTR2BPDK1PDK2PDK3
SCHEMBL846217 0.79 DPP4 (0.45) HTR2CHTR2BPDK1PDK2PDK3
SCHEMBL2675967 0.78 NOS1 (0.52) HTR2CHTR2BPDK1PDK2PDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173813-B2 selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants NEURAXON, INC. (CA) 2012-05-08 US disclosed
US-8173813-B2 selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants NEURAXON, INC. (CA) 2012-05-08 US disclosed
US-8173813-B2 selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants NEURAXON, INC. (CA) 2012-05-08 US disclosed
WO-2008116308-A1 QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2008-10-02 WO disclosed
US-20080234237-A1 QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2008-09-25 US disclosed
US-20080234237-A1 QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2008-09-25 US disclosed
US-20080234237-A1 QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234237-A1 QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NOS1, NOS2, NOS3 HTR2C 1041/4885HTR2B 1332/4885PDK1 2261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.